Nature Communications · 2020 · 80 citations · 25 references
MedicineInternal MedicinePharmacologyClinical PharmacologyInflammationRheumatologyInflammatory ArthritisInflammatory BiomarkersJoint DiseaseMetabolic InflammationRheumatoid ArthritisAnti-inflammatory TherapeuticsEarly Rheumatoid ArthritisInflammatory Synovial PathologyLipid ProfilingPathotype CharacterizationRheumatoid Arthritis TherapySpecialized Pro-resolving MediatorsSynovial Biomarkers
Abstract Biomarkers are needed for predicting the effectiveness of disease modifying antirheumatic drugs (DMARDs). Here, using functional lipid mediator profiling and deeply phenotyped patients with early rheumatoid arthritis (RA), we observe that peripheral blood specialized pro-resolving mediator (SPM) concentrations are linked with both DMARD responsiveness and disease pathotype. Machine learning analysis demonstrates that baseline plasma concentrations of resolvin D4, 10S, 17S-dihydroxy-docosapentaenoic acid, 15R-Lipoxin (LX)A 4 and n-3 docosapentaenoic-derived Maresin 1 are predictive of DMARD responsiveness at 6 months. Assessment of circulating SPM concentrations 6-months after treatment initiation establishes that differences between responders and non-responders are maintained, with a decrease in SPM concentrations in patients resistant to DMARD therapy. These findings elucidate the potential utility of plasma SPM concentrations as biomarkers of DMARD responsiveness in RA.
25
Marti A. Hearst, Susan Dumais, E. Osuna et al. · IEEE Intelligent Systems and their Applications · 1998 · 6.9K citations
A New Initiative on Precision Medicine
Francis S. Collins, Harold Varmus · New England Journal of Medicine · 2015 · 5.2K citations · Full text
Kristin P. Bennett, Colin Campbell · ACM SIGKDD Explorations Newsletter · 2000 · 689 citations